Tuesday, September 22, 2015 10:18:14 AM
LTG, we know you are not in healthcare, but how does a value analysis committee approve Alf/Transenterix when it is the same cost of davinci and same technology (or a step back in technology)? It is not going to happen
Also, how will TRXC now manufacture two completely different end effectors?
IMO, TRXC and Laviollette made a play for Titan (b/c they knew Surgibot was not going to be well rec'd by market). Titan rejected the offer and also put a shareholder rights plan in place to protect themselves. TRXC was now stuck and had to go with a plan B which was buying ALF.
Will be curious to see what happens to the stock price of TRXC.
CBD Life Sciences Inc. (CBDL) Launches High-Demand Mushroom Gummy Line for Targeted Wellness Needs, Tapping into a Booming $20 Billion Market • CBDL • Oct 31, 2024 8:00 AM
Nerds On Site Announces Q1 Growth and New Initiatives for the Remainder of 2024 • NOSUF • Oct 31, 2024 7:01 AM
Innovation Beverage Group Receives Largest Shipment of its Top-Selling Bitters to Date in the U.S.-Ready to Meet Growing Demand from Expanding Distribution Network • IBG • Oct 30, 2024 12:22 PM
Element79 Gold Corp to Update Investors on the Emerging Growth Conference on October 31, 2024 • ELMGF • Oct 30, 2024 9:08 AM
CBD Life Sciences Inc. (CBDL) Announces Grand View Research Report Findings on High - Growth CBD Equine Market, Aiming to Drive Unprecedented Shareholder Value • CBDL • Oct 29, 2024 10:19 AM
Integrated Ventures Announces Partnership And Lease Agreement with Driptide Wellness - Leading Health and Wellness Provider. • INTV • Oct 29, 2024 8:45 AM